Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
10/24/2022 - 06:00 AM
BEDFORD, Mass. --(BUSINESS WIRE)--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2022 financial results after the close on Monday, November 7, 2022 . Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.
Listeners can register for the webcast via this link . Those who plan on participating are advised to join 15 minutes prior to the start time. Analysts wishing to participate in the question and answer session should use this link . A replay of the webcast will be available via the Company’s investor website approximately two hours after the call’s conclusion for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.
View source version on businesswire.com : https://www.businesswire.com/news/home/20221024005315/en/
Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
ICR Westwicke
Chris Brinzey , 339-970-2843
Managing Director
chris.brinzey@westwicke.com
Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com
Source: Ocular Therapeutix, Inc.
OCUL Rankings
#4005 Ranked by Stock Gains
OCUL Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Bedford
About OCUL
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib